Financials Shanghai General Healthy Information and Technology Co., Ltd.

Equities

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 04/06/2024 am IST			5-day change	1st Jan Change
28.69 ^CNY	-1.14%		-12.64%	-31.26%

29/04	Shanghai General Healthy Information and Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
29/04	Shanghai General Healthy Information and Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	3,826	4,931	4,094	5,677	3,902	-	-
Enterprise Value (EV) ¹	3,826	4,931	4,094	5,677	3,902	3,902	3,902
P/E ratio	29.9 x	42.2 x	35.4 x	94.9 x	30.8 x	22.3 x	21.3 x
Yield	-	-	0.3%	0.24%	0.31%	0.31%	-
Capitalization / Revenue	-	10.1 x	12.7 x	18.5 x	10.2 x	7.65 x	7.66 x
EV / Revenue	-	10.1 x	12.7 x	18.5 x	10.2 x	7.65 x	7.66 x
EV / EBITDA	-	34.6 x	30.2 x	77.4 x	29.7 x	18.4 x	20.7 x
EV / FCF	-	-	-	-	-	-	-
FCF Yield	-	-	-	-	-	-	-
Price to Book	-	5.47 x	4.07 x	5.39 x	3.31 x	2.8 x	2.62 x
Nbr of stocks (in thousands)	1,36,000	1,36,000	1,36,000	1,36,000	1,36,000	-	-
Reference price ²	28.13	36.26	30.10	41.74	28.69	28.69	28.69
Announcement Date	19/04/21	09/03/22	28/04/23	29/04/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	-	489.8	322.4	307.6	380.7	510.3	509.4
EBITDA ¹	-	142.4	135.6	73.38	131.3	212.3	188.6
EBIT ¹	-	143.8	132.1	67.64	145	213.9	209.3
Operating Margin	-	29.36%	40.97%	21.99%	38.09%	41.91%	41.09%
Earnings before Tax (EBT) ¹	-	143.8	132	67.85	144.9	213.9	209.3
Net income ¹	95.74	117.6	115.7	60	127.1	174.5	183.6
Net margin	-	24.02%	35.89%	19.51%	33.38%	34.2%	36.03%
EPS ²	0.9400	0.8600	0.8500	0.4400	0.9300	1.285	1.350
Free Cash Flow	-	-	-	-	-	-	-
FCF margin	-	-	-	-	-	-	-
FCF Conversion (EBITDA)	-	-	-	-	-	-	-
FCF Conversion (Net income)	-	-	-	-	-	-	-
Dividend per Share ²	-	-	0.0900	0.1000	0.0900	0.0900	-
Announcement Date	19/04/21	09/03/22	28/04/23	29/04/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Net Debt	-	-	-	-	-	-	-
Net Cash position	-	-	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-
Free Cash Flow	-	-	-	-	-	-	-
ROE (net income / shareholders' equity)	-	13.6%	12.1%	5.82%	11.4%	12.8%	13.1%
ROA (Net income/ Total Assets)	-	-	9.94%	-	10.3%	11.3%	-
Assets ¹	-	-	1,164	-	1,234	1,545	-
Book Value Per Share ²	-	6.630	7.390	7.740	8.680	10.30	11.00
Cash Flow per Share ²	-	0.4000	-0.2700	-0.2600	2.980	2.300	1.140
Capex ¹	-	81.4	66.7	36.4	38.1	35.3	30.6
Capex / Sales	-	16.61%	20.7%	11.84%	10%	6.92%	6%
Announcement Date	19/04/21	09/03/22	28/04/23	29/04/24	-	-	-

¹CNY in Million²CNY

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

28.69 CNY

Average target price

40.18 CNY

Spread / Average Target

+40.05%

	1st Jan change	Capi.
SHANGHAI GENERAL HEALTHY INFORMATION AND TECHNOLOGY CO., LTD.	-31.26%	539M
ABBOTT LABORATORIES	-6.03%	180B
MEDTRONIC PLC	+1.08%	109B
BECTON, DICKINSON AND COMPANY	-2.19%	68.93B
DEXCOM, INC.	-5.98%	46.41B
CENCORA, INC.	+12.31%	45.43B
HOYA CORPORATION	+7.38%	43.26B
METTLER-TOLEDO INTERNATIONAL, INC.	+15.98%	30.05B
TERUMO CORPORATION	+16.10%	25.19B
ZIMMER BIOMET HOLDINGS, INC.	-6.79%	23.34B